Compare iShares MSCI ACWI ETF (ACWI) vs Alcon AG (ALC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Alcon AG — how do they compare? iShares MSCI ACWI ETF trades at $160.86, while Alcon AG trades at $74.32 (market cap $36.44B). The key difference: Alcon AG pays a 0.48% dividend while iShares MSCI ACWI ETF pays none, and iShares MSCI ACWI ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ACWI | ALC | |
|---|---|---|
52-Week High | $161.44 | $90.12 |
52-Week Low | $132.04 | $62.02 |
Market Cap | — | $36.44B |
Sector | — | Health |
Enterprise Value | — | $40.28B |
Dividend Yield | — | 0.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $161.65, up 0.34% today, with strong technical momentum showing bullish moving average signals. The ETF benefits from robust global earnings growth and investor inflows into equity ETFs, particularly in technology sectors. Recent institutional activity includes Bank of New York Mellon adjusting its position, while technical indicators show overbought conditions with RSI above 74.
The outlook remains positive given strong EPS growth and reasonable valuation at 15.5x forward P/E. Key risks include overbought technical conditions and market concentration in technology. Institutional sentiment appears constructive with continued ETF inflows supporting the global equity rally.
ALC trades at $73.59, down slightly by 0.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $86.67 implying 17.8% upside. Recent Q2 2026 earnings beat estimates with EPS of $0.84 versus $0.77 expected, and the company raised its 2026 profitability outlook, driving positive investor sentiment. Revenue growth has been steady, reaching $10.40 billion in 2025, though net income margin dipped to 5.92%.
The outlook is positive given strong earnings beats, raised guidance, and bullish analyst ratings, but risks include elevated P/E of 57.52, high RSI levels suggesting overbought conditions, and margin pressures from rising costs. Institutional ownership trends and recent collaborations, like with RxSight, support growth, yet macroeconomic and competitive factors warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →
